文献速递泌尿生殖与妇科肿瘤放疗

单次19 Gy高剂量率近距离治疗局限性前列腺癌的多中心长期结局

Long-term outcomes from a multicentre study of HDR monotherapy with a single fraction of 19 Gy for localized prostate cancer.
PubMed 文献 · Radiother Oncol · 2026-01-18

这项多中心回顾性研究纳入英国五个中心320例接受单次19 Gy高剂量率近距离治疗的局限性前列腺癌患者,中位随访94个月。5年和8年生化无进展生存率分别为77.1%和66.5%,局部无复发生存率分别为96.1%和90.9%。单次方案耐受性可,但高危患者疗效不等同于标准多分次方案,其角色应受限。

要点

  • 单次19 Gy HDR近距离治疗5年bPFS为77.1%,8年为66.5%。
  • 低危患者bPFS显著优于中高危患者(HR 12.55,95%CI 1.74-90.05,p=0.012)。
  • 晚期≥2级泌尿生殖毒性发生率为19.3%,生活质量评分一过性下降后恢复基线。

核心结论

  • 单次19 Gy HDR近距离治疗耐受性可并提供疾病控制,但高危疾病单次方案不等同于标准多分次方案,其角色应保持有限。

研究设计与样本

  • 多中心回顾性研究,纳入英国五个中心320例接受单次19 Gy HDR近距离治疗的局限性前列腺癌患者,中位随访94个月。

主要发现

  • 5年和8年bPFS分别为77.1%和66.5%,LRFS分别为96.1%和90.9%,NRFS分别为98.3%和97.3%,DMFS分别为95.9%和93.8%,OS分别为91.4%和87.0%。
  • 低危患者bPFS显著优于中高危患者(HR 12.55,95%CI 1.74-90.05,p=0.012),其他结局无显著差异。
  • MR扫描显示亚厘米盆腔淋巴结与较差的bPFS、LRFS、DMFS和OS相关,GS≥8预测较差的OS。
  • 急性和晚期≥2级泌尿生殖毒性发生率分别为3.1%和19.3%,胃肠道毒性分别为0.8%和1.5%。
  • 治疗后生活质量评分恶化:IPSS增加7分(p<0.001),IIEF减少9分(p=0.043),FACT-P减少3分(p=0.02),后恢复至基线。

关键数值与推荐

  • 单次19 Gy HDR近距离治疗作为标准化方案用于局限性前列腺癌。
  • 当代实践对大多数低危患者倾向于主动监测。

临床怎么用

  • 单次19 Gy HDR近距离治疗可用于部分局限性前列腺癌患者,但高危患者应优先考虑标准多分次方案。
  • 治疗前应评估盆腔淋巴结状态和Gleason评分以指导风险分层。
  • 治疗后需监测泌尿生殖和胃肠道毒性及生活质量变化。

局限性

  • 回顾性研究设计可能引入选择偏倚。
  • 仅纳入英国五个中心患者,结果外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate long-term clinical outcomes, toxicity, and prognostic factors in patients with localized prostate cancer treated with single-fraction high-dose-rate (HDR) brachytherapy. METHODS: This multicentre retrospective study included patients from five UK centres who received a single 19 Gy HDR brachytherapy fraction under a standardized protocol. Kaplan-Meier estimates were calculated at median 5 and 8 years for biochemical progression-free survival (bPFS), local recurrence-free survival (LRFS), nodal recurrence-free survival (NRFS), distant metastasis-free survival (DMFS), and overall survival (OS). Prognostic factors were assessed using Cox regression. Toxicities were graded using CTCAEv3.0. Quality of life (QoL) was evaluated using IPSS, IIEF, and FACT-P questionnaires. RESULTS: A total of 320 patients were included, with a median follow-up of 94 months. Five- and 8-year rates were: bPFS 77.1%/66.5%, LRFS 96.1%/90.9%, NRFS 98.3%/97.3%, DMFS 95.9%/93.8%, and OS 91.4%/87.0%. Low-risk patients had significantly better bPFS than intermediate and high-risk (HR12.55, 95%CI:1.74-90.05,p = 0.012), though no significant differences were seen in other outcomes. Subcentimetre pelvic lymph nodes on MR scan were associated with poorer bPFS, LRFS, DMFS, and OS. GS ≥ 8 predicted worse OS. Acute and late ≥ grade 2 GU toxicities occurred in 3.1% and 19.3% of patients, respectively; GI toxicities in 0.8% and 1.5%. QoL scores worsened post-treatment: IPSS + 7 points (p < 0.001), IIEF -9 points (p = 0.043), and FACT-P -3 points (p = 0.02) and returned to baseline. CONCLUSION: Single-fraction 19 Gy HDR brachytherapy was tolerable and provided disease control, though contemporary practice favors active surveillance for most low-risk patients. For higher-risk disease, a single fraction is not equivalent to standard multifraction regimens, indicating its role should remain limited.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Sittiwong W, Lydon A, Wylie J, et al. Long-term outcomes from a multicentre study of HDR monotherapy with a single fraction of 19 Gy for localized prostate cancer. Radiother Oncol. 2026. PMID: 41558582. doi:10.1016/j.radonc.2026.111385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。